
FDA ODAC Votes 4 to 5 Against UGN-102 for Recurrent LG-IR-NMIBC
In a narrow 4 to 5 vote, the Oncologic Drugs Advisory Committee (ODAC) decided that the overall benefit-risk of the investigational therapy UGN-102 (intravesical mitomycin) is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle …